文章：

T细胞重定向疗法后多发性骨髓瘤的可测量残留病灶检测

Measurable Residual Disease Testing in Multiple Myeloma Following T-Cell Redirecting Therapies

原文发布日期：27 September 2024

DOI: 10.3390/cancers16193288

类型: Article

开放获取: 是

英文摘要：

Several novel T-cell-based therapies have recently become available for multiple myeloma (MM). These T-cell redirecting therapies (TRTs) include chimeric antigen receptor T-cells (CAR-T) and bispecific antibodies (BiAbs). In both clinical trial and real-world data, these therapies have demonstrated high rates of deep clinical response, and some are now approved for second-line treatment for relapsed MM. The deep and sustained clinical responses these therapies are capable of inducing will require sophisticated response monitoring to provide meaningful information for patient care. Obtaining measurable residual disease (MRD) negativity has been validated as an independent positive prognostic marker for progression-free survival (PFS) and overall survival (OS) in both newly diagnosed and relapsed refractory patients with multiple myeloma. Assessment for MRD negativity was performed in all of the trials for FDA-approved TRT. Here, we summarize pertinent data for MRD assessment following TRT in MM and provide a rationale and structured framework for conducting MRD testing post TRT.

摘要翻译： 

近年来，针对多发性骨髓瘤（MM）的多种新型T细胞疗法已进入临床应用阶段。这类T细胞重定向疗法（TRT）主要包括嵌合抗原受体T细胞（CAR-T）和双特异性抗体（BiAb）。临床试验与实际应用数据显示，这些疗法能诱导深度临床缓解，部分已获批用于复发多发性骨髓瘤的二线治疗。由于此类疗法可产生持久深度的临床应答，需要采用精密的疗效监测手段为临床决策提供有效依据。在初诊及复发难治性多发性骨髓瘤患者中，达到可测量残留病灶（MRD）阴性已被证实是无进展生存期（PFS）和总生存期（OS）的独立正向预后指标。所有获得FDA批准的T细胞重定向疗法临床试验均纳入了MRD阴性评估。本文系统综述了多发性骨髓瘤T细胞重定向疗法后MRD评估的相关数据，并构建了治疗后MRD检测的理论框架与标准化实施方案。

原文链接：

Measurable Residual Disease Testing in Multiple Myeloma Following T-Cell Redirecting Therapies